Poseida Therapeutics Inc. (PSTX)
Poseida Therapeutics Statistics
Share Statistics
Poseida Therapeutics has 97.47M shares outstanding. The number of shares has increased by 0.52% in one year.
| Shares Outstanding | 97.47M |
| Shares Change (YoY) | 0.52% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 55.06% |
| Shares Floating | 64.7M |
| Failed to Deliver (FTD) Shares | 600 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.46 and the forward PE ratio is null. Poseida Therapeutics's PEG ratio is -0.05.
| PE Ratio | -2.46 |
| Forward PE | n/a |
| PS Ratio | 4.68 |
| Forward PS | 2.4 |
| PB Ratio | 2.92 |
| P/FCF Ratio | -3.18 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Poseida Therapeutics has an Enterprise Value (EV) of 343.97M.
| EV / Sales | 5.32 |
| EV / EBITDA | -3.15 |
| EV / EBIT | -3.73 |
| EV / FCF | -3.61 |
Financial Position
The company has a current ratio of 3.18, with a Debt / Equity ratio of 0.82.
| Current Ratio | 3.18 |
| Quick Ratio | 3.18 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | -0.78 |
| Debt / FCF | -0.9 |
| Interest Coverage | -14.94 |
Financial Efficiency
Return on Equity is -119.02% and Return on Invested Capital is -58.09%.
| Return on Equity | -119.02% |
| Return on Assets | -45.07% |
| Return on Invested Capital | -58.09% |
| Revenue Per Employee | $184.87K |
| Profits Per Employee | $-352.66K |
| Employee Count | 350 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 107K |
| Effective Tax Rate | -0.09% |
Stock Price Statistics
The stock price has increased by 358.94% in the last 52 weeks. The beta is 0.54, so Poseida Therapeutics's price volatility has been higher than the market average.
| Beta | 0.54 |
| 52-Week Price Change | 358.94% |
| 50-Day Moving Average | 6.66 |
| 200-Day Moving Average | 3.82 |
| Relative Strength Index (RSI) | 75.33 |
| Average Volume (20 Days) | 1.8M |
Income Statement
In the last 12 months, Poseida Therapeutics had revenue of 64.7M and earned -123.43M in profits. Earnings per share was -1.37.
| Revenue | 64.7M |
| Gross Profit | -92.07M |
| Operating Income | -129.5M |
| Net Income | -123.43M |
| EBITDA | -109.04M |
| EBIT | -114.65M |
| Earnings Per Share (EPS) | -1.37 |
Balance Sheet
The company has 44.47M in cash and 85.42M in debt, giving a net cash position of -40.95M.
| Cash & Cash Equivalents | 44.47M |
| Total Debt | 85.42M |
| Net Cash | -40.95M |
| Retained Earnings | -594.29M |
| Total Assets | 293.58M |
| Working Capital | 172.44M |
Cash Flow
In the last 12 months, operating cash flow was -92.17M and capital expenditures -3.07M, giving a free cash flow of -95.23M.
| Operating Cash Flow | -92.17M |
| Capital Expenditures | -3.07M |
| Free Cash Flow | -95.23M |
| FCF Per Share | -1.06 |
Margins
Gross margin is -142.29%, with operating and profit margins of -200.15% and -190.76%.
| Gross Margin | -142.29% |
| Operating Margin | -200.15% |
| Pretax Margin | -190.6% |
| Profit Margin | -190.76% |
| EBITDA Margin | -168.52% |
| EBIT Margin | -200.15% |
| FCF Margin | -147.18% |
Dividends & Yields
PSTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -40.73% |
| FCF Yield | -31.43% |
Analyst Forecast
The average price target for PSTX is $9, which is -5.3% lower than the current price. The consensus rating is "Hold".
| Price Target | $9 |
| Price Target Difference | -5.3% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.33 |
| Piotroski F-Score | 4 |